<DOC>
	<DOCNO>NCT02246218</DOCNO>
	<brief_summary>This open-label study consist transition period RAVICTI , follow safety extension period least 6 month 24 month treatment RAVICTI , depend age enrollment . It design capture information important evaluating safety , pharmacokinetics efficacy young child . Subjects follow referred Investigator management UCD assessment high blood ammonia may eligible study . Subjects eligible study include patient range newborn &lt; 2 year age either diagnose clinically suspect UCD .</brief_summary>
	<brief_title>A Study Safety , Efficacy Pharmacokinetics Glycerol Phenylbutyrate Pediatric Subjects Under 2 Years Age With Urea Cycle Disorders ( UCDs )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Urea Cycle Disorders , Inborn</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>Male female subject 2 year age Signed informed consent subject 's parent/legal guardian UCD diagnosis suspect diagnosis subtype , except Nacetyl glutamate synthetase deficiency . If UCD previously confirm genetic testing , consent must obtain parent/legal guardian prior perform genetic testing . If genetic test inconsistent excludes UCD diagnosis , subject withdrawn study . Use investigational drug within 30 day Day 1 Uncontrolled infection ( viral bacterial ) condition know precipitate hyperammonemic crisis . Once precipitating factor medically control , patient present crisis eligible . Any clinical laboratory abnormality Grade 3 great severity accord Common Terminology Criteria Adverse Events ( CTCAE ) v4.03 , except Grade 3 elevation ammonia liver enzymes , define level 520 time upper limit normal alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gamma glutamyl transpeptidase ( GGT ) clinically stable subject Any clinical laboratory abnormality medical condition , discretion Investigator , may put subject increase risk participate study Known hypersensitivity phenylacetate ( PAA ) phenylbutyrate ( PBA ) Liver transplantation , include hepatocellular transplant Subjects hemodialysis time initiate RAVICTI Subjects RAVICTI UCD management Currently treat CarbagluÂ® ( carglumic acid )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Urea Cycle Disorder</keyword>
	<keyword>UCD</keyword>
	<keyword>GT4P</keyword>
	<keyword>Buphenyl</keyword>
	<keyword>Glycerol Phenylbutyrate</keyword>
	<keyword>Ravicti</keyword>
	<keyword>Hyperammonemia</keyword>
	<keyword>Sodium Phenylbutyrate</keyword>
	<keyword>GPB</keyword>
	<keyword>HPN-100</keyword>
</DOC>